First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into clinical development LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas ...

ProQR Therapeutics (PRQR) 2025 Conference May 08, 2025 11:30 AM ET Speaker0 Alright. Welcome everybody to day two of the Citizens Life Science Conference. My name is John Walden. I'm a biotech analyst here, and we're pleased to have ProQure Therapeutics joining us and CEO, Daniel DeBoer. This is a story that we've been covering for quite some time. I think they have a very exciting technology and a very exciting 2025 with getting into the clinic with your Aximer platform, seeing the first clinical data in a ...

Table of Contents | | | March 31, | December 31, | | --- | --- | --- | --- | | | | 2025 | 2024 | | | | €1,000 | €1,000 | | Assets | | | | | Property, plant and equipment | 7 | 13,608 | 14,113 | | Investments in financial assets | 17 | — | — | | Non-current assets | | 13,608 | 14,113 | | Cash and cash equivalents | 5 | 132,414 | 149,408 | | Prepayments and other receivables | 6 | 5,137 | 3,747 | | Other taxes | | 530 | 690 | | Current assets | | 138,081 | 153,845 | | Total assets | | 151,689 | 167,958 | | Eq ...

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer€ 132.4 million cash and cash equivalents as of end Q1 providing runway into mid-2027, plus additional potential milestones from Lilly partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Thera ...

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thursday, May 8 at 11:30 AM EDT. A live webcast of the Company’s fireside chat will be available from the “Investors & M ...

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Tuesday, June 3, 2025 at 1530 CEST at the offices of Allen Overy Shearman Sterling LLP, in Amsterdam, the Netherlands. All relevant documents and information for the ...

Core Insights - ProQR Therapeutics has appointed Dennis Hom as Chief Financial Officer and Dr. Cristina Lopez Lopez as Chief Medical Officer to advance its Axiomer platform and RNA editing programs into clinical stages [1][2][3] Leadership Appointments - Dennis Hom brings over 25 years of financial leadership experience, having raised more than $4.5 billion in capital and executed transactions totaling over $57 billion in disclosed value [2] - Dr. Cristina Lopez Lopez has over 20 years of experience in translational R&D, previously serving as Global Head of Neurodegeneration at Johnson & Johnson and holding senior roles at Roche and Novartis [3] Transition of Current Executives - Current CFO Jurriaan Dekkers and Chief Corporate Development Officer René Beukema will step down but remain during a transitional period to ensure continuity [4][5] Axiomer Technology Overview - ProQR is pioneering Axiomer™, a next-generation RNA base editing technology that allows specific single nucleotide edits in RNA, potentially leading to new medicines for various diseases [5][7] - Axiomer™ Editing Oligonucleotides (EONs) utilize the human cell's ADAR machinery to correct disease-causing mutations in RNA, modulating protein expression or altering protein functions [5]

Core Viewpoint - ProQR reported a quarterly loss of $0.10 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, marking an earnings surprise of -42.86% [1] Financial Performance - The company posted revenues of $4.6 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 51.53%, compared to revenues of $3.54 million a year ago [2] - Over the last four quarters, ProQR has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - ProQR shares have declined approximately 30.2% since the beginning of the year, contrasting with the S&P 500's decline of -4.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $11.57 million, and for the current fiscal year, it is -$0.36 on revenues of $28.29 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which ProQR belongs, is currently in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact ProQR's stock performance [5]

Financial Reporting and Compliance - The financial statements have been prepared in accordance with IFRS, requiring estimates and assumptions that may differ from actual results[538] - There have been no material adjustments to prior period estimates for any of the periods included in the Annual Report[538] - The Company uses non-GAAP financial measures alongside IFRS measures to present its financial position and operating results[24] - The Company maintains its books and records in euro, presenting financial statements in this currency as its functional currency[25] Risks and Uncertainties - Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from expectations[32] - The Company faces risks related to geopolitical developments, including economic sanctions and trade barriers that could impact operations[37] - The impact of health epidemics and global supply chain pressures may slow or halt operations and activities[37] - The Company has not made any updates to forward-looking statements after the date of the Annual Report[36] Clinical Trials and Collaborations - The Company relies on contract research organizations (CROs) for timely enrollment in clinical trials, which may affect execution timelines[33] - The collaboration with Eli Lilly and Company includes potential milestone and royalty payments from commercial product sales[33]

Exhibit 99.1 ProQR Announces Year End 2024 Operating and Financial Results LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2025 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2024, and provided a business update. "As we continue to advance our Axiomer ADAR-mediated RNA editing platfo ...